Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus

Virology Journal

Volumn 10, Issue , 2013, Pages

  Yang, Song ^a,b   Niu, Shumeng ^a   Guo, Zhihua ^a   Yuan, Ye ^a   Xue, Kun ^a   Liu, Sinan ^a   Jin, Hong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cellular immune response; Cytotoxic T lymphocytes; Heterosubtypic immunity; Influenza virus; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS PROTECTION; FEMALE; IMMUNIZATION; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; SURVIVAL RATE; VIRUS LOAD; VIRUS REPLICATION;

INFLUENZA A VIRUS; MUS; NEWCASTLE DISEASE VIRUS; ORTHOMYXOVIRIDAE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 84884303756     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-291     Document Type: Article

References (38)

1. A distinct lineage of influenza A virus from bats. Tong SX, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO, Proc Natl Acad Sci U S A 2012 109 4269 4274 22371588
2. Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. Zhu XY, Yu WL, McBride R, Li Y, Chen LM, Donis RO, Tong S, Paulson JC, Wilson IA, Proc Natl Acad Sci U S A 2013 110 1458 1463 10.1073/pnas.1218509110 23297216
3. Anti-influenza virus effect of aqueous extracts from dandelion. He W, Han H, Wang W, Gao B, J Virol 2011 8 538 558 10.1186/1743-422X-8-538
4. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical Swine H1N1 based vaccines. Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, Nistal-Villán E, Palese P, Basler CF, García-Sastre A, PLoS Pathog 2010 6 http://dx.doi.org/10.1371/ journal.ppat.1000745 21203490
5. Orthomyxoviridae: the viruses and their replication. Palese P, Shaw ML, Fields virology, Howley DMKM, 5 2007 1647 1689
6. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. Bodewes R, Kreijtz JH, Geelhoed-Mieras MM, van Amerongen G, Verburgh RJ, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, J Virol 2011 85 2695 2702 10.1128/JVI.02371-10 21228239
7. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A(H5N1) viruses. Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstin A, Stephenson I, Szretter K, Cox NJ, Rudenko LG, Klimov A, Katz JM, Vaccine 2006 24 6588 6593 10.1016/j.vaccine.2006. 05.039 17030078 (Pubitemid 46107146)
8. Proective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/ 96-like H5N1 influenza virus CD8+ T cell expressing gamma interferon. Seo SH, Peiris M, Webster RG, J Virol 2002 76 4886 4890 10.1128/JVI.76.10.4886-4890.2002 11967305 (Pubitemid 34441694)
9. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Kreijtz JH, Bodewes R, van den Brand JM, de Mutsert G, Baas C, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, Vaccine 2009 27 4983 4989 10.1016/j.vaccine.2009. 05.079 19538996
10. Vaccine development for protecting swine against influenza virus. Chen Q, Madson D, Miller CL, Harris DL, Anim Health Res Rev 2012 13 181 195 10.1017/S1466252312000175 23253165
11. Intraocular vaccination with an inactivated highly pathogenic avian influenza virus induces protective antibody responses in chickens. Hikono H, Mase M, Matsuu A, Nakayama M, Saito T, Vet Immunol Immunopathol 2013 151 83 89 10.1016/j.vetimm.2012.10.005 23159237
12. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L, J Virol 2012 9 322 334 10.1186/1743-422X-9-322
13. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge. Prabakaran M, Kolpe AB, He F, Kwang J, Vaccine 2013 31 1385 1392 10.1016/j.vaccine.2013.01.003 23328313
14. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. Ge J, Deng G, Wen Z, Tian G, Wang Y, Shi J, Wang X, Li Y, Hu S, Jiang Y, Yang C, Yu K, Bu Z, Chen H, J Virol 2007 81 150 158 10.1128/JVI.01514-06 17050610 (Pubitemid 44975155)
15. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL, J Virol 2010 9 9217 9220
16. Human airway epithelial cells present antigen to influenza virus-specific CD8+ CTL inefficiently after incubation with viral protein together with ISCOMATRIX. Rimmelzwaan GF, Boon AC, Geelhoed MM, Voeten JT, Fouchier RA, Osterhaus AD, Vaccine 2004 29 2769 2775 (Pubitemid 38900653)
17. Streptococcus pyogense and lactobacillus rhamnosus differentially induce maturation and production of Th1-type cytokines and chemokines in human monocyte-derived dendritic cells. Veckman V, Miettinen M, Pirhonen J, Siren J, Matikainen S, Julkunen I, J Leukoc Biol 2004 75 764 771 14966192 (Pubitemid 38580056)
18. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. Osterlund P, Pirhonen J, Ikonen N, Ronkko E, Strengell M, Makela SM, Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, J Virol 2010 84 1414 1422 10.1128/JVI.01619-09 19939920
19. IL-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Seitz MLP, Dewald B, Towbln H, Towbin H, Gallati H, Baggiolini M, Eur J Immunol 1995 25 1129 1132 10.1002/eji.1830250443 7737285
20. Mechanism of protective immunity against influenza virus infection in mice without antibodies. Epstein SL, Lo CY, Misplon JA, Bennink JR, J Immunol 1998 160 322 327 9551987 (Pubitemid 28116745)
21. Assessment of seasonal influenza A virus-specific CD4 T- cell resonses to 2009 pandemic H1N1 Swine-Origin influenza A virus. Ge X, Tan V, Bollyky PL, Standifer NE, James EA, Kwok WW, J Virol 2010 84 3312 3319 10.1128/JVI.02226-09 20071564
22. Heterosubtypic immunity to influenz A virus: where do we stand? Grebe KM, Yewdell JW, Bennink JR, Microbes Infect 2008 10 1024 1029 10.1016/j.micinf. 2008.07.002 18662798
23. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, J virology 2008 82 5161 5166 10.1128/JVI.02694-07 18353950 (Pubitemid 351705225)
24. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, Chan PL, Lam KT, Guan J, Zhang L, Guan Y, Yuen KY, Peiris JS, Lau YL, J virol 2010 84 6527 6535 10.1128/JVI.00519-10 20410263
25. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. De Groot AS, Ardito M, McClaine EM, Moise L, Martin WD, Vaccine 2009 27 5740 5747 10.1016/j.vaccine.2009.07.040 19660593
26. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, Savidis-Dacho H, Zips ML, Crowe BA, Kreil TR, Ehrlich HJ, Barrett PN, Falkner FG, PLoS One 2011 6 http://dx.doi.org/10.1371/journal.pone.0016247 22242145
27. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Brewoo JN, Powell TD, Jones JC, Gundlach NA, Young GR, Chu H, Das SC, Partidos CD, Stinchcomb DT, Osorio JE, Vaccine 2013 31 1848 1855 10.1016/j.vaccine.2013.01.038 23376279
28. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A, Proc Natl Acad Sci U S A 2007 104 1 246 251 10.1073/pnas.0609330104 17200302 (Pubitemid 46068017)
29. Protection of mice against influenza A virus challenge by vaccination with baculovius-expressed Mz protein. Slpushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ, Vaccine 1995 13 1399 1402 10.1016/0264-410X(95)92777-Y 8578816
30. Aduvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. Katz JM, Lu X, Young SA, Galphin JC, J Infect Dis 1997 175 352 363 10.1093/infdis/175.2.352 9203656 (Pubitemid 27052241)
31. Co-expression of interleukin-2 by a bicistronic plasmid increases the efficacy of DNA immunization to prevent influenza virus infections. Henke A, Rohand N, Zell R, Wutzler P, Intervirology 2006 49 249 252 10.1159/000092487 16601357 (Pubitemid 43742511)
32. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. Chow YH, Huang WL, Chi WK, Chu YD, Tao MH, J Virol 1997 71 169 178 8985336
33. Infection of hla-dr1 transgenic mice with a human isolate of influenza A virus (H1N1) primes s diverse CD4 T-cell repertoire that includes CD4 T cell with heterosubtypic cross-reactivity to avian(H5N1) influenza virus. Richards KA, Chaves FA, Sant AJ, J Virol 2009 83 6566 6577 10.1128/JVI.00302-09 19386707
34. Haterosubtypic immunity against human influenza A viruses, indcluding recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymhocyte and macrophage function. Sambhara S, Kurichhh A, Miranda R, Tumpey T, Rowe T, Renshaw M, Arpino R, Tamane A, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D, Cell Immunol 2001 211 143 153 10.1006/cimm.2001.1835 11591118 (Pubitemid 32977345)
35. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM, J Clin Microbiol 1999 37 937 943 10074505 (Pubitemid 29140593)
36. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J, J Infect Dis 2001 183 368 376 10.1086/318084 11133367 (Pubitemid 32105595)
37. CDC, CDC Protocol for realtime RT PCR for influenza A (H1N1)-revision 2009
38. The development of a rapid SYBR Green I-based quantitative PCR for detection of duck circovirus. Wan C, Huang Y, Cheng L, Fu G, Shi S, Chen H, Peng C, Lin F, Lin J, J Virol 2011 8 465 470 10.1186/1743-422X-8-465